CytRx Clinical Update
Edison | Jun 25, 2015 07:50AM ET
Cardiac safety data support investment case
CytRx released cardiotoxicity data and interim positive efficacy results from the Phase II GBM and combination Phase Ib aldoxorubicin studies. Our focus remains on the ongoing Phase III second-line soft tissue sarcoma (STS) trial, with data expected in H216. While our fundamental view on the drug’s potential has not changed, the supplied cardiotoxicity data supports its intended mechanism of action. That is, by acting as a safer form of doxorubicin, aldoxorubicin may displace it in STS and potentially other oncology indications. We have amended our valuation slightly, resulting in an rNPV of $381m (from $375m previously).
No cardiotoxicity in 200 evaluable patients to date
The newly-presented cardiac safety data from ASCO show that aldoxorubicin has not provoked cardiotoxicity in patients treated to date, including at cumulative doses well above recognised cardiac safety limits for doxorubicin. Doxorubicin causes toxicity in 6-20% of patients when the cumulative total dose is 500mg/m2; however, the majority of the 200 evaluable aldoxorubicin-treated patients received doses above 1,500mg/m2 without any clinically significant cardiotoxicity.
Signs of efficacy in GBM Phase IIb interim data
Interim data from 18 subjects with unresectable glioblastoma multiforme (GBM) showed that two subjects achieved a complete response (CR), although 14 patients discontinued therapy. CytRx believes that some of the discontinuations resulted from a mistaken assessment of tumour progression, when pseudo-progression (with tumour destruction) was occurring instead. CytRx will assess approaches to better differentiate these events in a future study, which could be a pivotal GBM trial that combines aldoxorubicin with bevacizumab. The firm and its investigators believe that aldoxorubicin can cross the blood-brain-barrier (BBB) to deliver treatment effects, justifying continued clinical development.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.